Partnering Programs and Technologies
The ATPI seeks to develop and facilitate effective partnerships that are strategically important to NCI and where the prospects for accelerating translational research in cancer & AIDS is high. This involves identifying research and development needs and opportunities in the life sciences marketplace and bridging key NCI programs and technologies to potential external partners for possible collaboration. A range of business mechanisms are available to facilitate partnerships as appropriate.
The Frederick National Laboratory for Cancer Research (FNLCR) has a wide range of research programs, advanced technologies and innovative platforms that support NCI’s mission, from basic research to translational and clinical studies. Opportunities exist to partner in most program areas, which include extensive capabilities in drug and vaccine discovery and development, biomarker discovery and development, molecular profiling and molecular diagnostics, in-vitro and in-vivo cancer modeling systems, platform technologies in genomics, proteomics, imaging, nanotechnology, bioinformatics, histopathology, and many others.
- Center for Advanced Preclinical Research (CAPR)
- Nanotechnology Characterization Laboratory (NCL)
- Genomics Research Center (GRC)
- Optical Microscopy and Imaging Laboratory (OMAL)
- Advanced Biomedical Computing Center (ABCC)
- AIDS Cancer Vaccine Program (ACVP)
- Biopharmaceutical Development Program (BDP)
Technology development plays an important role in achieving the mission of the ATPI. Opportunities exist to partner on new technologies under development and on NCI inventions which may require further development (see: Featured Technologies for Partnering).
Director Business Development
Frederick National Laboratory for Cancer Research